Andrew Peter Mallon

I am a scientist, pharmacist and serial entrepreneur in biotechnology companies, specializing in creating and/or identifying early value and effectiveness with therapies in disease areas that have a high unmet clinical need. The combination of my business acumen and scientific expertise is a critical combination in early stage drug discovery and development. The development of PI3K-Akt pro-survival activators has been the culmination of many years of scientific endeavor that aims to provide us with a valuable therapeutic. Calista Therapeutics and our team is specialized in CNS research and development. The main focus of my work over the past 18 years has been is on the pathophysiology and pharmacology regulatory proteins, like PI3K and Akt, and their diseases, like Alzheimer’s disease (AD).

I invented and characterized a novel PI3K-Akt prosurvival activator. Subsequently, through screening and modeling, we have identified 31 drugs that are the subject of this proposal for the treatment of AD. I provide contributors with a reliable partner in this proposal because I am the inventor of this technology, and have been working in this field since my first days as a PhD student and during my time as a researcher and Adjunct Assistant Professor at Brown University Medical School. I have an in depth knowledge of the science and drug development landscape that will allow this project to move beyond these experiments to the patients.

January 2017